ORIGINAL RESEARCH

Transparency in clinical trials

Pavlov ChS1, Varganova DL2, Svistunov AA1, Gluud C3
About authors

1 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

2 Ulyanovsk State Clinical Hospital, Ulyanovsk, Russia

3 Сlinical Trial Unit, Coppenhagen, Denmark

Correspondence should be addressed: Daria L. Varganova
3-Internatsionala str. 7, Ulyanovsk, 432063; ur.ay@hcitad

About paper

Author contribution: Pavlov ChS – original concept, manuscript writing and editing; Varganova DL – literature analysis, manuscript writing; Svistunov AA, Gluud C – part in the concept and structure of the paper, manuscript editing.

Received: 2021-05-02 Accepted: 2021-05-25 Published online: 2021-10-13
|

In the age of information technology development, healthcare professionals around the world have the opportunity to simultaneously access advanced scientific developments, modern achievements, and the results of new clinical trials. The clinical guidelines of the international medical communities are based on the results of meta-analyses of clinical trial data. As new medical challenges emerge, clinical trial data are reviewed and re-analyzed. Unfortunately, to date, the results of not all studies are made public, or are presented selectively, indicating the positive effects of a particular technology (intervention), which makes it difficult to critically evaluate the results of work and makes the task of assessing the true effectiveness of the intervention more difficult. The problem of transparency of research data with the preservation of personal data of participants remains relevant for decades. This article is focused on possible ways of solving this problem and the analysis of the current situation in the world.

Keywords: clinical trials, transparency, openness

КОММЕНТАРИИ (0)